This profile was last updated on .
Is this you? Claim your profile.
210 Broadway Suite 201
CureVac, a clinical stage biopharmaceutical company from Tuebingen, Germany, is advancing the field of mRNA-based vaccination. The company uses its technology platforms for the development of novel therapeutic mRNA vaccines (RNActiveÂ®) for cancer and pro...
Find other employees at this company (83)
(153 Total References)
Study in Peer-Reviewed Journal Vaccine Demonstrates Decoding Mode of Action of mRNA Vaccines
Ingmar Hoerr, Ph.D., co-founder and CEO of CureVac, concluded, "Although we already initiated eight clinical trials in approximately 450 humans, we believe the knowledge generated from this study further strengthens the company to rapidly develop mRNA therapeutics and vaccines across a host of indications, comprising a broad range of formulations and with different routes of administration.
In the late 1990s, Dr. Ingmar Hoerr, Co-founder and CEO of CureVac, made an unexpected discovery during his doctoral research in biology, which was contrary to the established scientific belief at the time: RNA, which was generally thought to be a very unstable biomolecule, could be administered directly into tissue as a therapeutic vaccine or agent once the biological properties of the molecule were appropriately modified.
Furthermore, complicated formulations or molecular packaging were not required to achieve these results.
This discovery led to a new fundamental understanding of the potential of RNA to treat diseases and to generate prophylactic immunity.
These fascinating possibilities prompted the company's three founders, Ingmar Hoerr, Steve Pascolo and Florian von der Mülbe, to found CureVac without investors during the difficult market environment of 2000.
Dr. Ingmar Hoerr, CEO of ...
Dr. Ingmar Hoerr, CEO of CureVac, said "I believe these new results are excellent news for patients.
Ingmar Hoerr, PhD, ...
Ingmar Hoerr, PhD, MBA
Chairman / Chief Executive Officer
From this key discovery, Ingmar Hoerr
and Florian von der Mülbe built up a company that is now a global leader in the research and development of mRNA-based drugs.
Ingmar Hoerr received his PhD from the University of Tübingen and his MBA from Danube University, Krems, Austria.
Florian worked with Biotest GmbH and Roche AG before joining CureVac in 2000 - working with Ingmar Hoerr to build the business from the start.
Ingmar Hoerr, PhD, ...
Ingmar Hoerr, PhD, co-founder and CEO of CureVac, said, "We are delighted to welcome these esteemed experts to CureVac's Scientific Advisory Board during this time of significant growth and progress for CureVac.